IP Group plc has outlined potential future revenue opportunities from obesity drug candidates developed by Metsera, following Pfizer’s agreement to acquire Metsera for up to $7.3 billion...
IP Group plc has outlined potential future revenue opportunities from obesity drug candidates developed by Metsera, following Pfizer’s agreement to acquire Metsera for up to $7.3 billion...